Publikasi Scopus FKUI 2021 per tanggal 30 Juni 2021 (428 artikel)

Rinaldi I., Louisa M., Sari R.M., Arwanih E.
23475122400;41461551400;57208474079;57222314110;
Flt3-itd mutation and flt3 ligand plasma level were not associated with one-year survival of Indonesian acute myeloid leukemia patients
2021
OncoTargets and Therapy
14
1479
1486
Division of Hematology and Medical Oncology, Department of Internal Medicine, Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Division of Hematology and Medical Oncology, Department of Internal Medicine, Dharmais Cancer Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
Rinaldi, I., Division of Hematology and Medical Oncology, Department of Internal Medicine, Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Louisa, M., Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Sari, R.M., Division of Hematology and Medical Oncology, Department of Internal Medicine, Dharmais Cancer Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Arwanih, E., Division of Hematology and Medical Oncology, Department of Internal Medicine, Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
Objective: To analyze the association of FLT3-ITD mutation and FLT3 ligand plasma level with one-year survival of Indonesian acute myeloid leukemia (AML) patients. Methods: A prospective cohort study was conducted to determine the association between FLT-3-ITD mutation and FLT3 ligand plasma level with one-year survival of Indonesian AML patients. In the study, a total of 51 AML patients were obtained from two tertiary hospitals in Indonesia from year 2018 to 2020. Inclusion criteria were de novo AML male and female patients aged ≥18 years old. Exclusion criteria were prior myelodysplastic syndrome and patients that refused to participate in the study. FLT3-ITD genotype of patients was then analyzed using PCR method while FLT3 ligand plasma level was measured using ELISA method. Patients were then followed-up for 1 year or until death occurred with survival as the measured outcome. Association between independent and dependent variable were analyzed by cox regression proportional hazard. Results: Eleven patients (21.5%) in this study had FLT3-ITD mutation. The median age of AML patients was 45 (18–71) years, and the median blast percentage was 50% (5–87%). After one-year follow-up, 33 (64.7%) patients had died. The median survival of AML patients was 6 months. Univariate analysis showed no association between FLT3-ITD mutation status (HR: 1.051; 95% CI: 0.483–2.286; P: 0.901) and FLT3 ligand plasma level (HR: 0.798; 95% CI: 0.347–1.837; p= 0.596), and age (HR: 1.283; 95% CI: 0.575–2.862; p= 0.542) with one-year survival of AML patients, but multivariate analysis showed association between GFR with one-year survival of AML patients in this cohort (HR: 4.053; 95% CI: 1.469–11.183; p= 0.007). Conclusion: One-year survival of AML patients in Indonesia is not affected by FLT3-ITD mutation and FLT3 ligand plasma level. However, GFR showed association with one-year survival of AML patient in this cohort study. © 2021 Rinaldi et al.
Acute myeloid leukemia; FLT3 Ligand Plasma; FLT3-ITD; One-year survival
Dove Medical Press Ltd
11786930
Article
Q2
954
4642